A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.

NCT02225652 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Women With Primary Breast Cancer

Interventions

DRUG: FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS